The recent scrutiny of Trump's Most Favored Nation (MFN) deals with pharmaceutical companies has raised several questions.
These agreements, which aim to lower drug prices, are now being closely examined for their potential impact on the healthcare landscape.
As the discussions unfold, stakeholders are eager to understand the long-term effects of these deals on both the industry and consumers.